Literature DB >> 8180780

L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases.

U Brinck1, E Eigenbrodt, M Oehmke, S Mazurek, G Fischer.   

Abstract

Using immunohistochemical and enzyme biochemical methods we investigated the expression of L- and M2-pyruvate kinase (PK) in normal renal tissue, renal cell carcinomas (RCCs; of clear cell, chromophilic cell and mixed cell type) and RCC metastases. L-PK was expressed in the proximal tubules of normal renal tissue and, to a variable extent, in 23/25 primary RCCs, in 1 RCC recurrence and in 10 RCC metastases. Staining intensity and percentage of stained tissue did not correlate with tumour grade. One renal oncocytoma and all extrarenal malignancies examined lacked L-PK immunoreactivity. M2-PK was mainly expressed in the distal tubules of the normal kidney and was found in all renal tumours as well as extrarenal malignancies. Quantitative biochemical investigations yielded a two- to seventeen-fold increase in PK activity in RCCs compared to the normal renal cortex taken from the same patient, whereas fructose-1,6-bisphosphatase and cytosolic glycerol-3-phosphate dehydrogenase activity was dramatically lower in RCCs. Otherwise, the activity of all other enzymes investigated (glucose-6-phosphate dehydrogenase, enolase and lactate dehydrogenase) was not significantly changed in the RCCs. The immunocytochemical results suggest that L-PK is a useful marker for RCC and its metastases, if acetone-fixed tissue is available. The quantitative changes of the concentration of PK and other enzymes in RCCs when compared with normal renal tissue probably reflect metabolic alterations related to tumour growth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180780     DOI: 10.1007/bf00193498

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  In vitro effect of extracellular AMP on MCF-7 breast cancer cells: inhibition of glycolysis and cell proliferation.

Authors:  F Hugo; S Mazurek; U Zander; E Eigenbrodt
Journal:  J Cell Physiol       Date:  1992-12       Impact factor: 6.384

Review 2.  New prospects in the management of metastatic renal cell carcinoma. Experimental and clinical data.

Authors:  F M Debruyne; M P Franssen; A J Beniers; J A Schalken; P H de Mulder
Journal:  Prog Clin Biol Res       Date:  1990

Review 3.  Immunotherapy of renal cell carcinoma.

Authors:  G P Haas; G G Hillman; B G Redman; J E Pontes
Journal:  CA Cancer J Clin       Date:  1993 May-Jun       Impact factor: 508.702

4.  Enhancement of renal medullary pyruvate kinase activity during cell proliferation induced by potassium depletion.

Authors:  H N Aithal; F G Toback; C Cryst
Journal:  Am J Physiol       Date:  1980-04

5.  Glycolysis as primary energy source in tumor cell chemotaxis.

Authors:  M E Beckner; M L Stracke; L A Liotta; E Schiffmann
Journal:  J Natl Cancer Inst       Date:  1990-12-05       Impact factor: 13.506

6.  Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.

Authors:  W Thoenes; S Störkel; H J Rumpelt
Journal:  Pathol Res Pract       Date:  1986-05       Impact factor: 3.250

Review 7.  Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.

Authors:  E Eigenbrodt; M Reinacher; U Scheefers-Borchel; H Scheefers; R Friis
Journal:  Crit Rev Oncog       Date:  1992

8.  Immunolocalization of prealbumin (transthyretin) in renal cell carcinoma.

Authors:  L C Ang; T Debowski; R Michalski
Journal:  Histopathology       Date:  1991-06       Impact factor: 5.087

9.  Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells.

Authors:  M Board; S Humm; E A Newsholme
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

10.  Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma.

Authors:  E Oosterwijk; D J Ruiter; J C Wakka; J W Huiskens-van der Meij; U Jonas; G J Fleuren; J Zwartendijk; P Hoedemaeker; S O Warnaar
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

View more
  26 in total

1.  The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.

Authors:  Corinne Beinat; Tom Haywood; Yun-Sheng Chen; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

2.  Mapping the extracellular and membrane proteome associated with the vasculature and the stroma in the embryo.

Authors:  Fabienne Soulet; Witold W Kilarski; Florence Roux-Dalvai; John M J Herbert; Izabela Sacewicz; Emmanuelle Mouton-Barbosa; Roy Bicknell; Patricia Lalor; Bernard Monsarrat; Andreas Bikfalvi
Journal:  Mol Cell Proteomics       Date:  2013-05-14       Impact factor: 5.911

3.  Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.

Authors:  Edward Sanders; Svenja Diehl
Journal:  Oncoscience       Date:  2015-02-17

4.  Site-specific characterization and quantitation of N-glycopeptides in PKM2 knockout breast cancer cells using DiLeu isobaric tags enabled by electron-transfer/higher-energy collision dissociation (EThcD).

Authors:  Zhengwei Chen; Qing Yu; Ling Hao; Fabao Liu; Jillian Johnson; Zichuan Tian; W John Kao; Wei Xu; Lingjun Li
Journal:  Analyst       Date:  2018-05-29       Impact factor: 4.616

Review 5.  Regulation and function of pyruvate kinase M2 in cancer.

Authors:  Weiwei Yang; Zhimin Lu
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

Review 6.  The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.

Authors:  S Mazurek; C B Boschek; E Eigenbrodt
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

7.  The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.

Authors:  K Koss; R F Harrison; J Gregory; S J Darnton; M R Anderson; J A Z Jankowski
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

8.  Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.

Authors:  J Roigas; S Deger; J Schroeder; A Wille; I Turk; B Brux; K Jung; D Schnorr; S A Loening
Journal:  Urol Res       Date:  2003-09-26

9.  PKM2 promotes stemness of breast cancer cell by through Wnt/β-catenin pathway.

Authors:  Zheng Zhao; Zhangjun Song; Zijun Liao; Zhigang Liu; Haifeng Sun; Baoxia Lei; Wenjuan Chen; Chengxue Dang
Journal:  Tumour Biol       Date:  2015-10-22

10.  Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia.

Authors:  Mark M Aloysius; Abed M Zaitoun; Timothy E Bates; Abdulkader Albasri; Mohammad Ilyas; Brian J Rowlands; Dileep N Lobo
Journal:  BMC Cancer       Date:  2009-09-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.